The Association between Serological Biomarkers and Primary Sjogren’s Syndrome Associated with Peripheral Polyneuropathy

Abstract EN

Background and Aim.

The sensitivity and specificity of biomarkers used for predicting peripheral neuropathy of Sjogren’s syndrome (SJS) patients remain unsatisfactory.

This study aimed to determine the prognostic value of circulating autoantibodies levels in SJS patients with peripheral neuropathy.

Methods.

Two hundred and fifty serological positive (either anti-Ro or anti-La positive) SJS patients’ data were collected retrospectively.

The titers of autoantibodies, electrophysiology reports, and clinical manifestation were reviewed.

Results.

The prevalence rate of peripheral neuropathy is 7.2% in our study.

Regarding classification of peripheral neuropathy, 12 had mixed sensorimotor polyneuropathy, six had cranial neuropathy.

After stepwise logistic regression analysis, anti-β2 glycoprotein I (aβ2GP I) and perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) were significantly associated with peripheral neuropathy in serology positive SJS (P=0.01, P=0.046, resp.).

Conclusion.

The occurrence of peripheral neuropathy among SJS patients is not frequent and easily overlooked.

Our study demonstrated that aβ2GP I and p-ANCA levels may imply the danger of the occurrence of neuropathy in SJS patients, and they can be considered a biomarker that should be added to the panel of conventional autoantibody in SJS patients.